Results 91 to 100 of about 16,917 (221)

Improvement of Dysgeusia after Thymectomy with Thymoma.

The Kurume Medical Journal, 1999
We present a case of 39-year-old woman with thymoma complaining of dysgeusia. This patient had suffered from dysgeusia for the previous 6 months. Thymectomy with the thymoma was performed, and her dysgeusia was improved within 6 months after the operation. The anti-acetylcholine-receptor antibody was reduced from 0.9 nmol/l to 0.4 nmol/l (normal: below
TAKAMORI, SHINZO, HAYASHI, AKIHIRO, TAYAMA, KOHSUKE, MITSUOKA, MASAHIRO, TANIGAWA, HIROKAZU, TAMURA, KOICHI, SHIROUZU, KAZUO   +6 more
openaire   +3 more sources

Impact of Co‐Morbid Immunocompromise in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

The Laryngoscope, Volume 136, Issue 10, Page 4279-4289, October 2026.
Among patients with surgically resected Human Papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), immunocompromised patients had significantly worse overall survival compared to the non‐compromised group; however, these exploratory findings should be interpreted cautiously.
Maxwell L. Weng, Tereza Vitkovska, Song Hon Hwang, Lauran K. Evans, Hong‐Ho Yang, Christopher Dann, Dipti Sajed, Maie A. St. John   +7 more
wiley   +1 more source

Target‐Specific Dermatological Adverse Event Reporting With T‐Cell–Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016–2026

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background T‐cell–engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid‐tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target‐specific dermatological adverse event reporting patterns remain poorly defined.
Saikat Mandal, Manideepa Maji, Arkadeep Dhali   +2 more
wiley   +1 more source

Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Enfortumab vedotin (EV) is a crucial treatment for patients with metastatic urothelial carcinoma (mUC). However, a significant proportion of patients experience adverse events (AEs). The identification of biomarkers for AEs is imperative for the detection and treatment of AEs at an early stage.
Kunihiro Odagiri, Toshiharu Morikawa, Taku Naiki, Yosuke Sugiyama, Yoshihiko Tasaki, Yoshihisa Mimura, Aya Naiki‐Ito, Takashi Nagai, Toshiki Etani, Keitaro Iida, Daiki Ishikawa, Yusuke Noda, Nobuhiko Shimizu, Maria Aoki, Masakazu Gonda, Rika Banno, Hiroki Kubota, Ryosuke Ando, Yukihiro Umemoto, Noriyasu Kawai, Yoko Furukawa‐Hibi, Takahiro Yasui   +21 more
wiley   +1 more source

Myasthenia Gravis With Thymoma, Manifesting as AChR-Ab-Positive, Distinct Bulbar Palsy Accompanied by Dysgeusia: A Case Series and Review of Literature

Frontiers in Neurology, 2018
In this review, we summarized three cases of myasthenia gravis (MG) with taste disorder and describe their clinical features in detail. Three MG patients presented with significant bulbar palsy symptoms, high AChR-Ab titers, and negative MuSK-Ab, were ...
Kai Zhu, Kai Zhu, Jiaxin Chen, Jiaxin Chen, Jingjing Li, Jingjing Li, Haiyan Wang, Haiyan Wang, Xin Huang, Xin Huang, Yan Li, Huiyu Feng, Huiyu Feng   +12 more
doaj   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Non‐Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head &Neck, Volume 48, Issue 9, Page 2541-2556, September 2026.
ABSTRACT Background In patients with locally advanced, non‐metastatic oropharyngeal squamous cell carcinoma (OPSCC), surgery‐based and nonsurgical treatment approaches have not been adequately compared in randomized Phase III clinical trials. Current clinical guidelines recommend various surgical and nonsurgical strategies across disease stages for ...
Primož Strojan, Avraham Eisbruch, June Corry, Sandra Nuyts, Pim de Graaf, Luiz P. Kowalski, Jonathan J. Beitler, Sweet Ping Ng, William M. Mendenhall, M. P. Sreeram, Karthik N. Rao, Anna Luíza Damaceno Araújo, Alfio Ferlito   +12 more
wiley   +1 more source

Burning mouth syndrome

South African Family Practice, 2011
Burning mouth syndrome (BMS) is a chronic condition characterised by a burning sensation of the tongue and other sites, usually without associated clinical or laboratory findings. These patients, mainly postmenopausal women, often present with dry mouth (
W.F.P. van Heerden, A.W. van Zyl
doaj   +1 more source

Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin‐4 Expression: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Sarcomatoid urothelial carcinoma (UC) is an extremely rare and aggressive subtype with a poor prognosis. Reports on the efficacy of enfortumab vedotin (EV) in this subtype remain limited. Case Presentation A 74‐year‐old man presented with gross hematuria and was diagnosed with metastatic sarcomatoid UC of the urinary bladder with ...
Sonin Chon, Shoichi Nagamoto, Takahisa Yamashita, Kenta Fujii, Kazuki Yokota, Kojiro Tachibana, Sachi Kitayama, Yohei Okada, Satoru Kawakami, Akihiro Yano   +9 more
wiley   +1 more source

Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial

Journal of Research in Medical Sciences, 2013
Background: Taste abnormalities are common among cancer patients after starting radiotherapy or chemotherapy. Considering the role of zinc and reports on its beneficial effects in taste perception, we evaluated the preventive effects of zinc sulfate on ...
Nadia Najafizade, Simin Hemati, Abbas Gookizade, Nezameddin Berjis, Mostafa Hashemi, Soheil Vejdani, Alireza Ghannadi, Armindokht Shahsanaee, Nafise Arbab   +8 more
doaj